Publication:
Clinical Case Seminar. Peculiar prolactinomas in patients with pituitary developmental gene mutations: From an adult endocrinologist perspective

dc.contributor.authorDoknic, Mirjana (6603478362)
dc.contributor.authorPekic, Sandra (6602553641)
dc.contributor.authorCivcic, Milorad (18436145000)
dc.contributor.authorPopovic, Vera (35451450900)
dc.date.accessioned2025-06-12T22:12:42Z
dc.date.available2025-06-12T22:12:42Z
dc.date.issued2012
dc.description.abstractContext: Congenital hypopituitarism is a syndrome which is associated with single or multiple pituitary hormone deficiencies. Mutations in a number of developmental genes have been linked to combined pituitary hormone deficiencies, the most common being mutation in the pituitary homeobox protein prophet of the Pit 1 gene (PROP1). PROP1 exhibits DNA-binding and transcriptional activities. On magnetic resonance imaging, most patients with PROP1 mutation have a hypoplastic pituitary gland. Occasionally, transient pituitary enlargement before definite involution is reported. Kallmann syndrome (KS) is a human developmental genetic disorder which is a clinically (isolated hypogonadotropic hypogonadism-IHH) and genetically heterogeneous disease. Routine neuroimaging in classical IHH is thought to be of limited clinical value and normal anatomy of the hypothalamic-pituitary region is often reported. For neither disorder are there many reports on imaging during adulthood. Nor are there any guidelines concerning long-term imaging follow-up in patients with developmental pituitary disorders. Objective: Our aim was to present unusual endocrine and imaging abnormalities which developed in adulthood in two patients with developmental pituitary disorders. Cases: We report a female with combined pituitary hormone deficiencies (GH, TSH, gonadotropin and ACTH), except for prolactin, as a consequence of PROP1 mutation, and a male with KS (anosmia and IHH) due to Kal 2 gene (fibroblast growth factor receptor 1- FGFR1) mutation, both of whom in adulthood presented with prolactinomas. CONCLUSION: Both patients with developmental gene mutations, after long-term correction of their sex steroid status, developed prolactinomas. Although the exact mechanism of pituitary tumorigenesis is not known, we speculate that sex steroids may have facilitated prolactinoma development from the prolactin cell pool which underwent uncontrolled proliferation in the setting of a developmental disorder.
dc.identifier.urihttps://doi.org/10.14310/horm.2002.1346
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84863432315&doi=10.14310%2fhorm.2002.1346&partnerID=40&md5=6c20e23df41c27e9535978455b67d0ed
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/9771
dc.subjectFGFR1 mutation
dc.subjectHypogonadism
dc.subjectHypopituitarism
dc.subjectProlactinoma
dc.subjectPROP1 mutation
dc.titleClinical Case Seminar. Peculiar prolactinomas in patients with pituitary developmental gene mutations: From an adult endocrinologist perspective
dspace.entity.typePublication

Files